PT1713458E - Método para aumentar a biodisponibilidade do ospemifeno - Google Patents

Método para aumentar a biodisponibilidade do ospemifeno Download PDF

Info

Publication number
PT1713458E
PT1713458E PT05701734T PT05701734T PT1713458E PT 1713458 E PT1713458 E PT 1713458E PT 05701734 T PT05701734 T PT 05701734T PT 05701734 T PT05701734 T PT 05701734T PT 1713458 E PT1713458 E PT 1713458E
Authority
PT
Portugal
Prior art keywords
ospemifene
food
compound
use according
ingestion
Prior art date
Application number
PT05701734T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1713458(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of PT1713458E publication Critical patent/PT1713458E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT05701734T 2004-02-13 2005-01-14 Método para aumentar a biodisponibilidade do ospemifeno PT1713458E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene

Publications (1)

Publication Number Publication Date
PT1713458E true PT1713458E (pt) 2008-05-07

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05701734T PT1713458E (pt) 2004-02-13 2005-01-14 Método para aumentar a biodisponibilidade do ospemifeno

Country Status (23)

Country Link
US (5) US8236861B2 (OSRAM)
EP (1) EP1713458B1 (OSRAM)
JP (2) JP5577011B2 (OSRAM)
CN (1) CN1925847A (OSRAM)
AT (1) ATE387910T1 (OSRAM)
AU (1) AU2005211958B2 (OSRAM)
BE (1) BE2015C033I2 (OSRAM)
BR (1) BRPI0507661A (OSRAM)
CA (1) CA2556089C (OSRAM)
CY (2) CY1111014T1 (OSRAM)
DE (1) DE602005005165T2 (OSRAM)
DK (1) DK1713458T5 (OSRAM)
ES (1) ES2302177T3 (OSRAM)
FR (1) FR15C0041I2 (OSRAM)
HU (1) HUS1500030I1 (OSRAM)
LT (1) LTC1713458I2 (OSRAM)
LU (1) LU92736I2 (OSRAM)
MX (1) MXPA06009274A (OSRAM)
NO (2) NO337656B1 (OSRAM)
PL (1) PL1713458T3 (OSRAM)
PT (1) PT1713458E (OSRAM)
RU (1) RU2385716C2 (OSRAM)
WO (1) WO2005077350A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
RU2006142706A (ru) 2004-05-04 2008-06-20 Хормос Медикал Лтд. (Fi) Новые составы оспемифена для перорального применения
JP2009514944A (ja) * 2005-11-09 2009-04-09 ホルモス メディカル リミテッド フィスペミフェン製剤
EA023472B1 (ru) * 2005-11-28 2016-06-30 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
BRPI0807675B1 (pt) * 2007-02-14 2021-05-18 Hormos Medical Ltd. método para a preparação de um composto derivado de trifenilbuteno
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
IL278577B2 (en) 2018-05-11 2025-07-01 Xenon Pharmaceuticals Inc Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
JP2022553569A (ja) 2019-11-08 2022-12-23 ゼノン・ファーマシューティカルズ・インコーポレイテッド うつ病性障害の治療方法
EP4291189A1 (en) 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
ES2255294T3 (es) * 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
US6219674B1 (en) 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
AU2002255593A1 (en) 2001-02-22 2002-09-12 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
AU2003227790B2 (en) 2002-06-06 2007-11-29 Hormos Medical Corporation Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Also Published As

Publication number Publication date
DE602005005165D1 (de) 2008-04-17
LTC1713458I2 (lt) 2017-06-26
NO337656B1 (no) 2016-05-23
NO339190B1 (no) 2016-11-14
ATE387910T1 (de) 2008-03-15
DE602005005165T2 (de) 2009-04-30
BE2015C033I2 (OSRAM) 2024-08-08
US20130324614A1 (en) 2013-12-05
MXPA06009274A (es) 2007-04-16
NO20151603L (no) 2006-11-03
CA2556089C (en) 2013-04-02
JP2007522190A (ja) 2007-08-09
JP5577011B2 (ja) 2014-08-20
BRPI0507661A (pt) 2007-07-17
CA2556089A1 (en) 2005-08-25
CY1111014T1 (el) 2015-06-11
AU2005211958A1 (en) 2005-08-25
PL1713458T3 (pl) 2008-08-29
DK1713458T3 (da) 2008-07-07
US20120270952A1 (en) 2012-10-25
WO2005077350A1 (en) 2005-08-25
US20140303259A1 (en) 2014-10-09
EP1713458B1 (en) 2008-03-05
US9241915B2 (en) 2016-01-26
LU92736I2 (fr) 2015-08-10
HUS1500030I1 (hu) 2015-08-28
US20050182143A1 (en) 2005-08-18
US8236861B2 (en) 2012-08-07
NO20063960L (no) 2006-11-03
CY2015027I2 (el) 2016-04-13
US20160101065A1 (en) 2016-04-14
LTPA2015023I1 (lt) 2015-08-25
RU2006132719A (ru) 2008-03-20
CN1925847A (zh) 2007-03-07
JP2014141533A (ja) 2014-08-07
AU2005211958B2 (en) 2010-11-25
US8772353B2 (en) 2014-07-08
EP1713458A1 (en) 2006-10-25
DK1713458T5 (da) 2008-09-29
RU2385716C2 (ru) 2010-04-10
US9855224B2 (en) 2018-01-02
US8470890B2 (en) 2013-06-25
FR15C0041I1 (OSRAM) 2015-07-17
ES2302177T3 (es) 2008-07-01
JP6023119B2 (ja) 2016-11-09
FR15C0041I2 (fr) 2015-11-13
CY2015027I1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
US8772353B2 (en) Method for enhancing the bioavalability of ospemifene
JP5762390B2 (ja) 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
Bjarnason et al. Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol‐fed rabbits
AU2017206480A1 (en) Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome
KR20070022220A (ko) 오스페미펜의 생물학적 이용가능성 강화방법
KR101304536B1 (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 간질환의 치료 또는 예방용 조성물
JPWO2007069744A1 (ja) メタボリックシンドローム予防・改善用組成物
EP1742618B1 (en) Liquid oral formulations of ospemifene
Lee et al. Scenario 4: Choice of hormone replacement therapy (HRT)
EP2399583B1 (en) Use of vaginally-administered insulin sensitizing agents
JP2024511326A (ja) トルセミドおよびクロモリンを含む代謝疾患予防または治療用組成物
JP2023553438A (ja) 少なくとも１つのグリシン若しくはその誘導体及び／又は少なくとも１つのｎ－アセチルシステイン若しくはその誘導体と、少なくとも１つのチモール及び／又はカルバクロールと、を使用する組成物及び方法
FYTILI SCHOOL OF MEDICINE 1st DEPARTMENT OF PROPAEDEUTIC INTERNAL MEDICINE Director: Professor P. Sfikakis
FRANKLIN Raloxifene Has Breast Ca Benefits but Stroke Risks
JP2019524860A (ja) 非アルコール性脂肪肝疾患の治療法